Main Uses of Xofigo

Xofigo is a therapeutic radiopharmaceutical used to treat a specific stage of prostate cancer known as metastatic castration-resistant prostate cancer (mCRPC). This condition occurs when the cancer no longer responds to medical or surgical treatments that lower testosterone levels and has spread to other parts of the body.

Targeted Bone Treatment

This treatment is specifically indicated for patients whose prostate cancer has spread to the bones (bone metastases) but has not spread to other internal organs, such as the lungs or liver. Because the active substance in Xofigo mimics calcium, it is selectively absorbed by areas of the bone where the cancer is active and the bone is rapidly turning over.

Potential Benefits

The primary goals of treatment with Xofigo involve managing the progression of the disease in the skeletal system and improving long-term outcomes for patients.

• Extension of Survival: Clinical evidence indicates that the treatment can extend the life expectancy of patients with mCRPC compared to standard care alone.
• Delay of Skeletal Events: By targeting bone metastases, the treatment helps delay the occurrence of symptomatic skeletal-related events. This includes complications such as pathological fractures or the need for radiation therapy to relieve bone pain.
• Localized Action: The alpha particles emitted by the drug have a very short range, meaning the radiation energy is concentrated primarily within the bone tumors themselves, minimizing exposure to surrounding healthy tissues and organs.

Eligibility Scope

Populations for whom use is allowed (as stated in label):

• Adult male patients (aged 18 or older) with castration-resistant prostate cancer (mCRPC).
• Patients with symptomatic bone metastases and no known visceral metastatic disease.
• Requires acceptable baseline hematologic status prior to and during treatment (e.g., ANC ge 1.5 imes 10^9/ L).

Populations for whom use is not recommended:

• Patients with only asymptomatic bone metastases or a low number of osteoblastic bone metastases (benefit not established).
• Concomitant use with chemotherapy or other systemic cancer therapies outside of a clinical trial.

Populations for whom use is contraindicated:

• Women who are or may become pregnant.
• Patients with known hypersensitivity to radium-223 dichloride or its excipients.
• Combination with abiraterone acetate and prednisone/prednisolone (as restricted by European regulators).

Age and Condition-Specific Eligibility

• Age-related Eligibility: The medicine is indicated for adult patients. Safety and efficacy have not been established in children or adolescents below 18 years of age.
• Organ Function: No dose adjustment is generally required for renal or hepatic impairment, but safety in severe impairment has not been established.
• Pregnancy and Lactation: Use is contraindicated in pregnancy and not to be used while breastfeeding.
• Eligibility-related Restrictions: Treatment must be discontinued if required hematologic recovery does not occur. Male patients must use effective contraception during and for 6 months after treatment.

Interactions with other medicines and products

The interaction profile of Xofigo is defined primarily by pharmacodynamic effects related to toxicity and timing requirements, rather than metabolic pathways. As an alpha-emitting isotope, Radium-223 Dichloride is not metabolized by the liver or kidneys, meaning no major pharmacokinetic interactions involving CYP enzymes or drug transporters are officially documented in regulatory sources.

Interaction Restrictions and Prohibitions

Official regulatory documents identify specific combinations that are either restricted or prohibited:

When treatment with the contraindicated combination is stopped, subsequent Xofigo administration is not initiated for at least 5 days following the last dose of that regimen. Caution is noted with co-administration of bisphosphonates due to a non-excluded risk of osteonecrosis of the jaw. Interaction risk related to fractures is further noted in patients with a history of osteoporosis or those with less than six bone metastases.

The mechanism of action for Radium-223 Dichloride involves a highly specific sequence of physical localization and targeted radiation. The drug is classified as a calcium mimetic; its chemical properties cause it to be preferentially absorbed by the mineral hydroxyapatite in the bone matrix, concentrating at sites of accelerated bone turnover. Once localized, the isotope decays, emitting alpha particles. These particles possess high linear energy transfer (LET), which efficiently induces complex DNA double-strand breaks (DSBs) in cells within the immediate microenvironment. The extensive DNA damage activates cellular processes leading to apoptosis in proliferating tumor cells and associated stromal cells. This physical mechanism is inherently self-limiting: the alpha particles travel less than 100 micrometers in tissue. This constraint physically confines the cytotoxic effect to the immediate vicinity of the deposit, ensuring the destructive energy is deployed precisely at the bone-tissue interface.

Administration and Dosing Schedule

Xofigo (radium-223 dichloride) is a radiopharmaceutical administered by intravenous (IV) injection and should only be handled and administered by authorized personnel in designated clinical settings. This medication is not diluted or mixed with any other solutions, as it is a ready-to-use solution for injection.

Official Dosing and Frequency

The recommended dose regimen is 55 kBq (1.49 microcurie) per kg body weight, given in a series of up to six injections.

Procedural Requirements

Before treatment initiation and before every subsequent dose, a hematological evaluation is mandatory. This evaluation ensures that the absolute neutrophil count, platelet count, and hemoglobin levels meet specific regulatory criteria. If blood counts do not recover within six weeks of the prior injection, treatment may be delayed or discontinued.

During the administration procedure, the IV access line must be flushed with isotonic saline both before and immediately after the Xofigo injection. As a precaution for radiation safety, patients should follow good hygiene practices—such as washing hands well and flushing the toilet several times—for at least one week following each injection. There are no general restrictions on proximity or personal contact with others following administration.

Research Evidence: Overview of Studies for Xofigo

The core research for Xofigo involved a large, international Phase III Randomized Controlled Trial (RCT). This research setting compares the medicine, administered alongside the best standard of care, against a placebo plus the best standard of care. This design allows researchers to examine how patterns in patient outcomes differed between the two groups. The studies evaluated several key outcomes, including the primary endpoint of Overall Survival (OS).

Research examined specific outcomes related to skeletal health, including tracking the Time to first Symptomatic Skeletal Event (SSE). An SSE is defined in this research context as the time until a patient might need external beam radiation for bone pain, experience a bone fracture, or require a tumor-related orthopedic procedure. Studies also explored changes in biomarkers such as Prostate-Specific Antigen (PSA) and Alkaline Phosphatase (ALP) levels, which are routinely monitored in this disease area. The overall findings describe patterns observed in the studies regarding these specific endpoints over the defined study period.

Study Populations and Research on Combination Therapy

The populations studied in the primary trials were adult men diagnosed with castration-resistant prostate cancer (mCRPC), where the disease had spread to the bones and was causing symptoms. The main research examined groups based on their prior treatment history, observing populations who were considered chemotherapy-naïve and comparing them to those who had received prior docetaxel.

Studies have also explored scenarios where Xofigo was evaluated in combination with other systemic therapies that treat mCRPC. However, one randomized trial that examined the concurrent use of Xofigo with abiraterone acetate and prednisone/prednisolone was stopped early. This study reported patterns associated with an increased occurrence of bone fractures and specific observations regarding patient outcomes in the combination group, which indicates that certainty remains low for some combination scenarios.

Evidence Gaps and Areas of Ongoing Research

Research is focused almost exclusively on patients with bone-dominant disease. The primary studies included patients with no known visceral metastatic disease (cancer spread to soft organs), meaning that the data for certain groups remain limited for this population. Furthermore, the evidence base for men with a very low number of bone metastases is limited and heterogeneous. Research continues to explore the long-term patterns observed.

Key Studies & References Radium-223 Dichloride (Xofigo) - NIH MedlinePlus Drug Information

Common questions about Xofigo (FAQ)

Q: Will Xofigo make me radioactive to other people?

A: According to official product information, there are no general restrictions on proximity or personal contact with others following your injection. The risk of radiation to other people is primarily related to potential contamination from spills or contact with bodily fluids, such as urine or feces. Basic safety and hygiene practices are typically mentioned in official guidelines to manage this minimal risk.

Q: What should I know about my bathroom use after receiving Xofigo?

A: Official guidance recommends that patients practice good hygiene for at least one week following each Xofigo injection. Official guidance notes that hygiene practices include washing hands thoroughly and flushing the toilet multiple times after each use. These steps are intended to mitigate the low contamination risk associated with the medicine leaving the body.

Q: Are there special precautions for people who handle bodily fluids after Xofigo?

A: Yes, official procedures state that people who may need to handle a patient’s bodily fluids, like caregivers or healthcare staff, should take precautions. Official procedures specify that universal precautions, such as gloves and protective gowns, are used when handling urine, feces, or vomit to help avoid contamination risks.

Q: Does Xofigo interact with common heart or blood pressure medications?

A: Regulatory documents do not list major interactions with common heart or blood pressure medicines. This is because Xofigo is a radiopharmaceutical that is not metabolized by major organs like the liver or kidneys, which is where many drug interactions occur. The full list of known restrictions and potential interactions is detailed in the official prescribing information.

Q: Why is calcium intake sometimes a concern during Xofigo treatment?

A: Xofigo is chemically a calcium mimetic, meaning it mimics calcium and is attracted to the bone matrix. Due to this mechanism, caution is noted in official documentation. Concerns regarding diet or supplements can be addressed by a patient's healthcare provider.

Q: Do official documents mention an improvement in bone pain?

A: Clinical studies examined the delay in the occurrence of a Symptomatic Skeletal Event (SSE). An SSE is defined as needing external beam radiation to manage bone pain or experiencing a bone fracture. The studies showed that patients receiving Xofigo experienced this event later than those on placebo, indicating an effect on the progression of skeletal disease.

Q: How is Xofigo different from other treatments for bone metastases?

A: Xofigo is a specialized radiopharmaceutical that uses short-range alpha particles. These alpha particles travel less than 100 micrometers (a tiny distance) in tissue, ensuring that the radiation is highly localized to the bone lesions. This mechanism is designed to deliver cytotoxic energy locally to tumor cells, thereby confining the radiation effect.

Q: Why is this drug only used for bone pain related to prostate cancer?

A: The medicine is officially indicated only for adult male patients with castration-resistant prostate cancer that has spread to the bones and is symptomatic. Its mechanism of action relies on targeting areas of high bone turnover, which are characteristic of metastatic bone lesions in this specific disease context.

Q: Does Xofigo affect cancer cells in other parts of the body?

A: The mechanism is designed to be highly localized. The alpha particles released by the drug travel less than 100 micrometers, which is a very short distance. The physical constraint means the destructive energy is primarily confined to the immediate vicinity of the deposit within the bone, which aligns with the indication for bone-dominant disease.

Q: What kind of side effects are the most common with Xofigo?

A: The most frequently reported side effects in clinical trials (occurring in 10% or more of patients) primarily involve the gastrointestinal system and the blood and lymphatic system. Common gastrointestinal effects include nausea, diarrhea, and vomiting. Hematological effects are related to the reduction of blood cell counts.

Q: Is Xofigo considered a 'cure' for prostate cancer or just for the bones?

A: Official study findings describe the medicine's role as one that prolongs life and delays the signs and symptoms of progressive disease. Official documents do not describe this medicine as a curative treatment for prostate cancer.

Q: What kind of fatigue should I expect during treatment with Xofigo?

A: Fatigue is not reported as a very common side effect in its own right, but it is known to occur as a symptom secondary to other common adverse reactions. For example, it can be associated with dehydration from gastrointestinal issues or low blood cell counts.

Q: Is the radiation from Xofigo considered 'targeted'?

A: Yes, the medicine is considered a targeted therapy based on its mechanism. Its active component acts like calcium, which causes it to be preferentially absorbed into the bone matrix at sites where cancer has caused rapid bone turnover. This accumulation at the diseased sites focuses the radiation effect where it is needed most.

Q: Why do doctors only use Xofigo when the cancer has spread to the bones?

A: Official documents explain that the medicine works by concentrating at sites of increased bone turnover, which is the physical characteristic of metastatic lesions in the bones. This mechanism is why the medicine is only used in patients where the cancer has spread to and is affecting the skeletal system.

Q: What is the longest period a person usually receives Xofigo treatments?

A: The official dose regimen involves a series of up to six injections administered once every four weeks. The total treatment period is approximately six months, as defined by the maximum six injections administered at four-week intervals.

Q: Does Xofigo have an impact on fertility?

A: Official documents state that male patients must use effective contraception during treatment and for six months following the final dose. Furthermore, official information notes that advice regarding sperm conservation may be sought before beginning treatment, which indicates a potential impact on fertility.

Q: What are the official warnings about Xofigo regarding new bone fractures?

A: Regulatory warnings exist regarding the risk of bone fractures. The medicine is believed to accumulate at sites of high bone turnover, which can include areas of existing or potential fracture. This may increase the risk of new bone fractures, particularly in patients with conditions like osteoporosis.

Q: Is Xofigo a common treatment choice for advanced prostate cancer?

A: Official documents classify Xofigo as a therapeutic option approved for advanced prostate cancer that has spread to the bones and is causing symptoms. Its approval is based on major international clinical trials and it is a known tool in the management of this specific stage of disease.

Q: What is the difference between Xofigo and external beam radiation?

A: Xofigo is administered as a systemic internal therapy, meaning it travels through the bloodstream to reach all bone lesions throughout the body. In contrast, external beam radiation is delivered from a machine outside the body to focus radiation on a small, specific area.

Q: What research is currently being done on Xofigo?

A: Research continues globally to explore the medicine's full potential and safety profile. Current studies are focused on evaluating its use in combination with other cancer therapies, such as combining it with other radiation delivery methods like Stereotactic Body Radiation Therapy (SBRT).

Q: Does Xofigo help patients live longer?

A: The primary Phase III study examined Overall Survival (OS) as a key outcome. The findings from the main Phase III study indicated a pattern of overall survival advantage for patients who received Xofigo compared to those who received a placebo. This finding was reported as a median increase of approximately 3.6 months in overall survival.

Q: What if a patient has bone pain that is not from prostate cancer?

A: The official indication restricts the use of Xofigo to symptomatic bone metastases caused by castration-resistant prostate cancer. The medicine's safety and effectiveness for bone pain or metastases resulting from any other type of cancer or condition have not been established in the official labeling.

Q: Are there age restrictions for receiving Xofigo?

A: The medicine is indicated only for adult patients, defined as 18 years and older. Official regulatory documents state that the safety and effectiveness of Xofigo have not been established for use in children or adolescents. No specific upper age limit is noted in the labeling.

Q: What percentage of patients experience significant side effects?

A: In clinical trials, the most common side effects, such as gastrointestinal effects and reduced blood cell counts, were reported in more than 10% of patients. The most serious adverse reactions, though less frequent, documented in regulatory documents include bone marrow failure.

Q: Can Xofigo be used if a patient has had previous radiation treatment?

A: The use of Xofigo may be cautioned in patients who have had prior treatments that could affect the bone marrow reserve. Official documents caution against use in patients with a history of extensive radiation that may have compromised the bone marrow's ability to produce new blood cells.

Q: Why is Xofigo not used if the cancer hasn't spread to the bones yet?

A: Regulatory documents clearly state that the treatment benefit has not been established for adult patients with only asymptomatic bone metastases. The drug's mechanism of action is dependent on concentrating in areas of high bone activity, which typically only occurs once the cancer has spread to the bones.

Q: What are the risks associated with exposure to the drug?

A: The overall risks of the medicine are divided into two main areas. The risk to others is primarily that of contamination from bodily fluids for about one week. The risks to the patient are the potential adverse reactions documented in clinical trials, mainly affecting the blood and gastrointestinal systems.

Official Storage and Handling

Official Disposal Instructions

This radiopharmaceutical's storage is strictly defined by regulatory bodies to ensure radiation safety, requiring it to be stored at room temperature in shielded containers. Disposal protocols classify the unused medicine and contaminated materials as radioactive waste, necessitating compliance with specific local and national regulations enforced by competent official organizations. All handling procedures must satisfy both radiation safety and pharmaceutical quality requirements.